Role of Bisoprolol and Dapagliflozin in the Management of Cardiometabolic Disorders: A Comprehensive Review

Cardiometabolic disorders comprise a spectrum of interrelated conditions such as hypertension, type 2 diabetes mellitus, heart failure, coronary artery disease, obesity, and metabolic syndrome, which collectively contribute to increased global morbidity and mortality. The close association between cardiovascular and metabolic abnormalities necessitates integrated therapeutic strategies that address both components simultaneously. Bisoprolol, a highly selective β1-adrenergic receptor blocker, is widely used in cardiovascular disorders due to its ability to reduce heart rate, myocardial contractility, and renin release with minimal metabolic adverse effects. Dapagliflozin, a sodium–glucose co-transporter-2 (SGLT2) inhibitor, initially developed as an antidiabetic agent, has demonstrated significant cardiovascular and renal protective benefits independent of glycemic control. This comprehensive review highlights the pharmacological profile, pharmacokinetics, pharmacodynamics, clinical applications, safety, drug interactions, and future perspectives of bisoprolol and dapagliflozin. Emphasis is placed on their complementary mechanisms of action and their combined role in the management of cardiometabolic disorders. The integration of these agents represents a rational and effective approach toward improving cardiovascular outcomes, metabolic control, and overall patient prognosis.